Physician profile
Julia Foldi
NPI 1710333455
$7,310.22
in general payments reported to CMS, 2019-2025
7 companies · $6,931 in 2025
The $6,931 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $379 · 2025: $6,931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,649 · Food and Beverage: $411 · Grant: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,649.45 |
| Food and Beverage | $410.77 |
| Grant | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $4,281.91 | 2025 | Enhertu |
| Genentech USA, INC. | $1,990.79 | 2025 | Perjeta, Herceptin, Kadcyla |
| Gilead Sciences, INC. | $580.00 | 2025 | Trodelvy |
| Astrazeneca Pharmaceuticals Lp | $328.35 | 2024-2025 | |
| Menarini Silicon Biosystems, INC. | $129.17 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Foldi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.